Work

Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase inhibitor (PARPi) and androgen receptor signaling inhibitor (ARSi) combination therapy.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.420

Authors: Weranja Ranasinghe, Mahsa Delavar, Mitchell G. Lawrence, Nicholas Choo, Birunthi Niranjan, Melissa Papagiris, Jenna Kraska, Hong Wang, Shivakumar Keerthikumar, Ganiraju C. Manyam, Patricia Troncoso, Peter S Shephard, Timothy C. Thompson, Renea Taylor, Brian Francis Chapin, Gail Risbridger

Institutions: Monash University, Peter MacCallum Cancer Centre, The University of Texas MD Anderson Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407701334

Cites:

Cited by:

Related to: 10